Multicenter Phase IB/II Study of AdV-Tk, a Gene-Mediated Cytotoxic Immunotherapy, Adjuvant to Surgical Resection for Patients With Newly Diagnosed High Grade Glioma
Purpose: The prognosis for malignant gliomas is poor, and overall survival remains less than 15 months despite improved diagnostic and treatment techniques, underscoring the need for novel therapeutic options. This multicenter, single-arm Phase Ib/II trial was conducted to assess the safety and eff...
| Main Author: | |
|---|---|
| Format: | Others |
| Language: | en |
| Published: |
Harvard University
2015
|
| Online Access: | http://nrs.harvard.edu/urn-3:HUL.InstRepos:15821599 |